Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

Last month, an average of about 350 people died each week from COVID, according to data from the CDC. With available vaccines and treatments, why are people still dying?

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...